Ann: ResApp Builds European Market Presence, page-46

RB, thanks for your post. I read this bit that makes me believe that it is not as simple as testing cost effectiveness but also its accuracy. Below is an excerpt of the announcement which makes me sweat a bit:

The observational stage of the evaluation will establish a baseline for the resource usage and costs associated with current care pathways for respiratory diagnosis in a UK A&E department, and also compare the accuracy of ResAppDx-EU to a clinical diagnosis.

Please understand that I have no 'quarrel' with the product. I agree it will have huge positive impact. I believe in the product. No question about it. I believe you have seen my post before and always, my doubt has always been with the way management done thing. I was getting happy lately because to me, they are doing it right finally and then out came this announcement. The last thing the company need now is another rejection at the end of the trial, which is a possibility, right?